Keywords: Vivus, Luramist, Acrux, Testosterone for women
Vivus returns rights to develop Luramist to Acrux
Article | 01 April 2010
The USA’s Vivus has terminated the development and commercialization agreement with FemPharm, a wholly-owned subsidiary of Australian drug company ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
